Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Cocoon Biotech is raising $4,495,285.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Ailis Tweed-Kent played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cocoon Biotech

Cocoon Biotech, Inc. is advancing silk fibroin as a material science platform with broad potential in the human health, animal health, agriculture, and consumer product industries. Silk’s unique properties offer the potential to transform our ability to formulate, deliver, and stabilize molecules, with resulting improvements in manufacturing processes, safety, and efficacy. Additionally, the remarkable strength and tunable material characteristics exhibited by silk enable impactful and far-reaching innovation.

To learn more about Cocoon Biotech, visit http://www.cocoonbiotech.com/

Contact:
Ailis Tweed-Kent, Chief Executive Officer
617-356-7346
ailis@cocoonbiotech.com
https://www.linkedin.com/in/ailis-tweed-kent-11432a8/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved